239 related articles for article (PubMed ID: 19127460)
1. Some controversial multiple testing problems in regulatory applications.
Hung HM; Wang SJ
J Biopharm Stat; 2009; 19(1):1-11; discussion 12-41. PubMed ID: 19127460
[TBL] [Abstract][Full Text] [Related]
2. Partition testing in dose-response studies with multiple endpoints.
Liu Y; Hsu J; Ruberg S
Pharm Stat; 2007; 6(3):181-92. PubMed ID: 17654696
[TBL] [Abstract][Full Text] [Related]
3. Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials.
Hung HM; Wang SJ; O'Neill R
J Biopharm Stat; 2007; 17(6):1201-10. PubMed ID: 18027226
[TBL] [Abstract][Full Text] [Related]
4. Challenge of multiple co-primary endpoints: a new approach.
Chuang-Stein C; Stryszak P; Dmitrienko A; Offen W
Stat Med; 2007 Mar; 26(6):1181-92. PubMed ID: 16927251
[TBL] [Abstract][Full Text] [Related]
5. Power and sample size when multiple endpoints are considered.
Senn S; Bretz F
Pharm Stat; 2007; 6(3):161-70. PubMed ID: 17674404
[TBL] [Abstract][Full Text] [Related]
6. Challenges to multiple testing in clinical trials.
James Hung HM; Wang SJ
Biom J; 2010 Dec; 52(6):747-56. PubMed ID: 20589856
[TBL] [Abstract][Full Text] [Related]
7. Hierarchical testing of multiple endpoints in group-sequential trials.
Glimm E; Maurer W; Bretz F
Stat Med; 2010 Jan; 29(2):219-28. PubMed ID: 19827011
[TBL] [Abstract][Full Text] [Related]
8. Testing non-inferiority and superiority for two endpoints for several treatments with a control.
Lawrence J
Pharm Stat; 2011; 10(4):318-24. PubMed ID: 20949636
[TBL] [Abstract][Full Text] [Related]
9. How to deal with multiple endpoints in clinical trials.
Neuhäuser M
Fundam Clin Pharmacol; 2006 Dec; 20(6):515-23. PubMed ID: 17109645
[TBL] [Abstract][Full Text] [Related]
10. Sample size determination in superiority clinical trials with multiple co-primary correlated endpoints.
Sozu T; Sugimoto T; Hamasaki T
J Biopharm Stat; 2011 Jul; 21(4):650-68. PubMed ID: 21516562
[TBL] [Abstract][Full Text] [Related]
11. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
Wang SJ; Hung HM; O'Neill R
J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
[TBL] [Abstract][Full Text] [Related]
12. Properties of multiple intersection-union tests for multiple endpoints in combination therapy trials.
Westfall PH; Ho SY; Prillaman BA
J Biopharm Stat; 2001; 11(3):125-38. PubMed ID: 11725927
[TBL] [Abstract][Full Text] [Related]
13. Adaptive methods: telling "the rest of the story".
Emerson SS; Fleming TR
J Biopharm Stat; 2010 Nov; 20(6):1150-65. PubMed ID: 21058111
[TBL] [Abstract][Full Text] [Related]
14. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
15. A note on one-sided tests with multiple endpoints.
Perlman MD; Wu L
Biometrics; 2004 Mar; 60(1):276-9; discussion 279-80. PubMed ID: 15032799
[TBL] [Abstract][Full Text] [Related]
16. Constructing multiple test procedures for partially ordered hypothesis sets.
Edwards D; Madsen J
Stat Med; 2007 Dec; 26(28):5116-24. PubMed ID: 17476650
[TBL] [Abstract][Full Text] [Related]
17. A new partition testing strategy for multiple endpoints.
Wang B; Cui X
Stat Med; 2012 Sep; 31(20):2151-68. PubMed ID: 22532094
[TBL] [Abstract][Full Text] [Related]
18. A note on P-values under group sequential testing and nonproportional hazards.
Gillen DL; Emerson SS
Biometrics; 2005 Jun; 61(2):546-51. PubMed ID: 16011703
[TBL] [Abstract][Full Text] [Related]
19. Gatekeeping testing via adaptive alpha allocation.
Li JD; Mehrotra DV
Biom J; 2008 Oct; 50(5):704-15. PubMed ID: 18932133
[TBL] [Abstract][Full Text] [Related]
20. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
Zhao Y; Grambsch PM; Neaton JD
Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
